Abstract
Introduction

Primary effusion lymphoma (PEL) is a rare type of B-cell lymphoma presenting as serous effusion without obvious tumor masses. It usually occurs in patients infected with human immunodeficiency virus (HIV), and human herpesvirus 8 (HHV-8) is also thought to play a causative role (1). Several Japanese reports have described HHV-8-negative lymphomas of the body cavities of immunocompetent patients as PEL (2). The HHV-8-positive PEL cell line TY-1 was derived from a Japanese patient with AIDS (3), but a patient with HHV-8-associated PEL has never been reported in Japan, as far as we know. Here, we describe a patient with HHV-8 and HIV-positive PEL who responded well to highly active anti retroviral therapy (HAART) and chemotherapy.
Case Report
. Southern blotting showed clonal rearrangement of the immunoglobulin heavy chain gene (Fig. 3) . Systemic computed tomography confirmed the absence of tumorous lesions and enlargement of the liver,
F i g u r e 1 . Cl i n i c a l c o u r s e o f t h e p a t i e n t . P l e u r a l e f f u s i o n a n d p l a s ma HHV-8 v i r a l l o a d d e c r e a s e d b y T HP -COP t h e r a p y a n d HAART .
F i g u r e 2 . Cy t o l o g i c a l s t u d y o f p l e u r a l e f f u s i o n . L a r g e a t y p ic a l l y mp h o i d c e l l s wi t h l a r g e i r r e g u l a r n u c l e i a n d p r o mi n e n t n u c l e o l i h a v e a b u n d a n t b a s o p h i l i c c y t o p l a s m ( A, P a p a n i c ol a o u s t a i n × 1 0 0 0 ; B , Ma y -Gr ü n wa l d s t a i n × 1 0 0 0 ) . I mmu n oh i s t o c h e mi c a l a n a l y s i s s h o ws t h a t c e l l b l o c k f r o m p l e u r a l e f f us i o n i n d i c a t e s L CA + ( C) , CD3
-( D) , L 2 6
-( E ) , a n d HHV-8 ( F ) l a t e n t n u c l e a r a n t i g e n ( L ANA) + .
F i g u r e 3 . An a l y s i s o f DNA f r o m c e l l s i n p l e u r a l e f f u s i o n . S o u t h e r n b l o t s s h o w g e n e r e a r r a n g e me n t u s i n g p r o b e s t o d e t e c t J H g e n e t o i mmu n o g l o b u l i n h e a v y c h a i n ( C, c o n t r o l h u ma n p l a c e n t a ; P , p a t i e n t ) . T h r e e b a n d s a r e e v i d e n t wi t h p r o b e s 2 a n d 3 .
F i g u r e 4 . S y s t e mi c c o mp u t e d t o mo g r a p h y f i n d i n g s . I ma g e s h o ws l a t e r a l p l e u r a l a n d l a r g e p e r i c a r d i a l e f f u s i o n s , b u t n o t u mo r ma s s o r e n l a r g e me n t o f l y mp h n o d e s , l i v e r a n d s p l e e n .
spleen, or lymph nodes (Fig. 4) (1) , and have been reported in Japan (7, 8) .
. The dosage of chemotherapy was reduced because of his poor performance status and renal insufficiency. He received 200 mg fluconazole and trimethoprim sulfamethoxazole (80 mg of trimethoprim and 400 mg of sulfamethoxazole) for the prophylaxis of fungal and Pneunocystis jirovecii infections. G-CSF was administered subcutaneously in a dose of 2 μg/kg to reduce the duration and degree of neutropenia. Pleural effusion transiently increased on day 8, but disappeared from day 15. Plasma HHV-8 DNA disappeared after two cycles of THP-COP therapy were completed. As of the time of the writing (February 2010), the patient remains free of HHV-8 DNA and eight cycles of THP-COP therapy were completed. After three cycles of THP-COP therapy, PET/CT demonstrated the absence of abnormal uptake. The patient thus achieved and sustained complete remission for 7 months.
Discussion
Non-Hodgkin's lymphoma (NHL) is 60-to 200-fold more prevalent among HIV-positive, than immunocompetent individuals and PEL accounts for about 4% of HIV-associated lymphoma (4). HHV-8 is a member of the Gammaherpesvirinae subfamily of Herpesviridae and it is associated with the pathogenesis of Kaposi's sarcoma (KS), PEL and multicentric Castleman's disease (5). Latency-associated nuclear antigen-1 and viral cyclin might also play roles in the pathogenesis of PEL (6). PEL is a large B-cell neoplasm usually presenting as serous effusions without detectable tumor masses. On the other hand, HHV-8-associated solid lymphomas in the absence of lymphomatous effusions have been termed as extracavitary PEL
To our knowledge, no Japanese patient with HHV-8-associated PEL has been described, which might be due to the low prevalence of HHV-8 infection in Japan. The preva- Japan until 1990 (Fig. 5) .
lence of HHV-8 infection in the general population varies throughout the world, being highest in Sub-Saharan Africa, where >50% of the population is infected (9). Seroprevalence is approximately 5-20% in the Mediterranean region (9), whereas the reported seroprevalence of HHV-8 among the general Japanese population is 1.4 -2.2% (10, 11). The incidence of HHV-8 among seropositive HIV-negative Japanese blood donors according to assays for anti-LANA antibodies is 0.2% (12). Multiplex PCR assays have also indicated the prevalence of HHV-8 to be 0.2% (13). This extremely low-prevalence of HHV-8 could explain why PEL is rare in Japan. In fact, KS among individuals with HIV/AIDS was extremely rare in
Despite (12) . In fact, the number of new instances of KS among HIVpositive patients has increased (Fig. 5) .
Although T a b l e 1 . L a b o r a t o r y F i n d i n g s o n Ad mi s s i o In conclusion, we describe HHV-8-associated PEL that developed in a patient who was infected with HIV. Although PEL is presently rare in Japan, the incidence might increase in the future.
